Odonate Therapeutics Inc represents values of innovation, dedication, and patient-centric approach in the field of pharmaceuticals. The company is committed to developing and commercializing medicines to improve the lives of patients with cancer. Odonate Therapeutics fosters a corporate philosophy that emphasizes the importance of scientific research, clinical advancement, and collaboration with healthcare professionals. With a focus on oncology, the company strives to bring transformative therapies to patients in need. Odonate Therapeutics Inc seeks to revolutionize cancer treatment through groundbreaking advancements, ensuring hope and improved outcomes for individuals facing this devastating disease.

Odonate Therapeutics Inc is primarily present in the United States.

Odonate Therapeutics Inc has achieved significant milestones in its journey. The company successfully developed and gained approval for its lead product, tesetaxel, a chemotherapy drug. Tesetaxel has demonstrated promising results in clinical trials, showcasing its potential as an effective treatment for diverse forms of cancer. Odonate Therapeutics Inc also secured strategic collaborations with renowned institutions and organizations, further enhancing its research and development capabilities. These achievements position Odonate Therapeutics Inc as a key player in the biopharmaceutical industry, dedicated to improving patient outcomes and advancing cancer therapeutics.

Odonate Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics for the treatment of cancer. The company was founded in 2013 and is headquartered in San Diego, California. Odonate's main product candidate, tesetaxel, is an oral chemotherapy drug currently in advanced clinical trials for the treatment of various types of cancer, including breast cancer. With a team of experienced professionals and a strong commitment to improving patient outcomes, Odonate Therapeutics Inc. is dedicated to bringing novel cancer therapies to market and making a positive impact in the field of oncology.

The main competitors of Odonate Therapeutics Inc in the market include pharmaceutical companies focused on developing and commercializing oncology treatments, such as Pfizer Inc, Merck & Co., Inc, and Novartis AG. These established players have a strong presence in the oncology market and offer a range of oncology therapeutics. However, Odonate Therapeutics Inc distinguishes itself by providing innovative therapies that specifically target and address unmet medical needs in the treatment of breast cancer.

Odonate Therapeutics Inc is primarily active in the healthcare industry.

The business model of Odonate Therapeutics Inc is focused on developing and commercializing innovative therapeutics for the treatment of cancer. The company is primarily engaged in the research, development, and clinical trials of its proprietary drug candidates, with a specific focus on the treatment of breast cancer. Odonate Therapeutics aims to address unmet medical needs and improve patient outcomes by delivering novel cancer treatments. By leveraging its expertise in oncology drug development, the company aims to create value for stakeholders and contribute to advancing the field of cancer therapeutics.

Odonate Therapeutics에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Odonate Therapeutics에 대한 현재 KUV는 계산할 수 없습니다.

Odonate Therapeutics에 대한 AlleAktien 품질 점수는 2/10입니다.

Odonate Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

Odonate Therapeutics의 현재 이익을 계산할 수 없습니다.

Odonate Therapeutics Inc is a biotechnology company that specializes in developing innovative therapies for cancer. The company focuses on developing drugs that can target and effectively fight cancer cells while being gentle on the patient's healthy tissue. The goal of Odonate Therapeutics is to improve the quality of life and prolong the survival time of cancer patients.

Odonate Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Odonate Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Odonate Therapeutics의 ISIN은 US6760791060입니다.

Odonate Therapeutics의 WKN은 A2H9FC입니다.

Odonate Therapeutics의 티커는 ODTC입니다.

지난 12개월 동안 Odonate Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Odonate Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Odonate Therapeutics의 현재 배당 수익률은 입니다.

Odonate Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Odonate Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Odonate Therapeutics은 '건강' 섹터에 속합니다.

Odonate Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Odonate Therapeutics는 0 USD를 배당금으로 지급했습니다.

Odonate Therapeutics의 배당금은 USD에 지급됩니다.